Search by Drug Name or NDC
NDC 72607-0100-00 TAZVERIK 200 mg/1 Details
TAZVERIK 200 mg/1
TAZVERIK is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Epizyme, Inc.. The primary component is TAZEMETOSTAT HYDROBROMIDE.
MedlinePlus Drug Summary
Tazemetostat is used to treat epithelioid sarcoma (a rare, slow-growing soft tissue cancer) in adults and children 16 years of age and older that has spread to nearby tissues or to other parts of the body and cannot be treated successfully with surgery. It is also used to treat certain types of follicular lymphoma (FL; a type of cancer that begins in the white blood cells) in adults whose cancer that has returned or did not respond to at least two other medications. Tazemetostat is also used to treat follicular lymphoma in adults that has returned or did not respond to treatment when no other treatment options are available. Tazemetostat is in a class of medications called EZH2 inhibitors. It helps to stop the spread of cancer cells.
Related Packages: 72607-0100-00Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Tazemetostat
Product Information
| NDC | 72607-0100 |
|---|---|
| Product ID | 72607-100_6656919b-73f1-4d41-9da9-944e72f0356d |
| Associated GPIs | 21533675200320 |
| GCN Sequence Number | 080675 |
| GCN Sequence Number Description | tazemetostat hydrobromide TABLET 200 MG ORAL |
| HIC3 | V11 |
| HIC3 Description | ANTINEOPLASTIC - PROTEIN METHYLTRANSFERASE INHIBIT |
| GCN | 47619 |
| HICL Sequence Number | 046312 |
| HICL Sequence Number Description | TAZEMETOSTAT HYDROBROMIDE |
| Brand/Generic | Brand |
| Proprietary Name | TAZVERIK |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | tazemetostat |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, FILM COATED |
| Route | ORAL |
| Active Ingredient Strength | 200 |
| Active Ingredient Units | mg/1 |
| Substance Name | TAZEMETOSTAT HYDROBROMIDE |
| Labeler Name | Epizyme, Inc. |
| Pharmaceutical Class | Methyltransferase Inhibitor [EPC], Methyltransferase Inhibitors [MoA], Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], Multidrug and Toxin Extrusion Transporter 2 K Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA211723 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 72607-0100-00 (72607010000)
| NDC Package Code | 72607-100-00 |
|---|---|
| Billing NDC | 72607010000 |
| Package | 240 TABLET, FILM COATED in 1 BOTTLE (72607-100-00) |
| Marketing Start Date | 2020-01-23 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |